<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02551094</url>
  </required_header>
  <id_info>
    <org_study_id>MHIPS-003</org_study_id>
    <nct_id>NCT02551094</nct_id>
  </id_info>
  <brief_title>Colchicine Cardiovascular Outcomes Trial (COLCOT)</brief_title>
  <acronym>COLCOT</acronym>
  <official_title>Colchicine Cardiovascular Outcomes Trial (COLCOT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montreal Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montreal Heart Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates whether long-term treatment with colchicine reduces rates of&#xD;
      cardiovascular events in patients after myocardial infarction. Patients who have suffered a&#xD;
      documented acute myocardial infarction within the last 30 days, are treated according to the&#xD;
      national guidelines and after having completed any planned percutaneous revascularization&#xD;
      procedures associated with their initial infarction will receive either colchicine (0.5 mg&#xD;
      per day) or matching placebo (1:1 allocation ratio) for an estimated 2 years period or until&#xD;
      the target of 301 primary endpoints has been reached.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atherosclerosis is the most common cause of myocardial infarction, stroke and peripheral&#xD;
      arterial disease. Research has clearly demonstrated that inflammation plays a key role in the&#xD;
      initiation, progression and manifestations of atherosclerosis. Atherosclerotic lesions begin&#xD;
      as an accumulation of lipid-laden cells (primarily macrophages) beneath the endothelium, and&#xD;
      progress with the further accumulation of cells, connective-tissue elements, lipids and&#xD;
      debris through immunological and inflammatory activation. Neutrophils and other inflammatory&#xD;
      cells have been shown to invade culprit atherosclerotic lesions in acute coronary syndromes.&#xD;
      It is likely that the inflammatory process is responsible for the high rate of cardiovascular&#xD;
      events despite significant advances in the treatment of risk factors such as&#xD;
      hypercholesterolemia and hypertension. It is vital to improve our understanding of the&#xD;
      inflammatory nature of atherosclerotic disease and modify the inflammatory process with&#xD;
      targeted therapies. Prospective cohort studies have consistently shown that high sensitivity&#xD;
      C-reactive protein (hs-CRP) and several other biomarkers of inflammation are independently&#xD;
      associated with increasing risk of future cardiovascular events in different populations.&#xD;
      This together with animal models showing that reduced inflammation has anti-atherosclerotic&#xD;
      effects, create the impetus to test the hypothesis that treatment of the underlying&#xD;
      inflammatory process will contribute to improved cardiovascular clinical outcomes. Colchicine&#xD;
      is an inexpensive, yet potent, anti-inflammatory drug approved for acute use in patients with&#xD;
      gout and chronic use in patients with Familial Mediterranean Fever. The mechanism of action&#xD;
      is through the inhibition of tubulin polymerization and potentially also through effects on&#xD;
      cellular adhesion molecules and inflammatory chemokines. Colchicine may also have direct&#xD;
      anti-inflammatory effects by inhibiting key inflammatory signaling networks known as the&#xD;
      inflammasome and pro-inflammatory cytokines. Through the disruption of the cytoskeleton,&#xD;
      colchicine is believed to suppress secretion of cytokines and chemokines as well as in vitro&#xD;
      platelet aggregation. Considerable work has highlighted the potential of colchicine in the&#xD;
      treatment of cardiovascular diseases mediated by pro-inflammatory processes. More recently&#xD;
      colchicine has been evaluated for its effect on cardiovascular events in patients with&#xD;
      coronary artery disease (CAD).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 4, 2015</start_date>
  <completion_date type="Actual">July 17, 2019</completion_date>
  <primary_completion_date type="Actual">July 17, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First Event of Cardiovascular Death, Resuscitated Cardiac Arrest, Acute Myocardial Infarction, Stroke, or Urgent Hospitalization for Angina Requiring Coronary Revascularization</measure>
    <time_frame>From randomization to occurence of first event, assessed up to 3.5 years</time_frame>
    <description>The descriptive statistics are the number of participants having at least one of the composites of the primary endpoint.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death (Total Mortality)</measure>
    <time_frame>From randomization to death, assessed up to 3.5 years</time_frame>
    <description>The descriptive statistics are the number of participants having deceased.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Death</measure>
    <time_frame>From randomization to death, assessed up to 3.5 years</time_frame>
    <description>The descriptive statistics are presented as the number of participants having had a cardiovascular death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resuscitated Cardiac Arrest</measure>
    <time_frame>From randomization to event, assessed up to 3.5 years</time_frame>
    <description>The descriptive statistics are presented as the number of participants having had resuscitated cardiac arrest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>From randomization to event, assessed up to 3.5 years</time_frame>
    <description>The descriptive statistics are presented as the number of participants having had myocardial infarction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>From randomization to event, assessed up to 3.5 years</time_frame>
    <description>The descriptive statistics are presented as the number of participants having had a stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urgent Hospitalization for Angina Requiring Coronary Revascularization</measure>
    <time_frame>From randomization to event, assessed up to 3.5 years</time_frame>
    <description>The descriptive statistics are presented as the number of participants having had urgent hospitalization for angina requiring coronary revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First Event of Cardiovascular Death, Resuscitated Cardiac Arrest, Acute MI or Stroke.</measure>
    <time_frame>From randomization to occurence of first event, assessed up to 3.5 years</time_frame>
    <description>The descriptive statistics are presented as the number of participants having had a first event of cardiovascular death, resuscitated cardiac arrest, acute MI or stroke.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>First Event of Deep Venous Thrombosis or Pulmonary Embolus</measure>
    <time_frame>From randomization to occurence of first event, assessed up to 3.5 years</time_frame>
    <description>The descriptive statistics are presented as the number of participants having had a first event of deep venous thrombosis or pulmonary embolus.</description>
  </other_outcome>
  <other_outcome>
    <measure>Atrial Fibrillation</measure>
    <time_frame>From randomization to event, assessed up to 3.5 years</time_frame>
    <description>The descriptive statistics are presented as the number of participants having had atrial fibrillation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart Failure Hospitalization</measure>
    <time_frame>From randomization to event, assessed up to 3.5 years</time_frame>
    <description>The descriptive statistics are presented as the number of participants having had heart failure hospitalization.</description>
  </other_outcome>
  <other_outcome>
    <measure>Coronary Revascularization</measure>
    <time_frame>From randomization to event, assessed up to 3.5 years</time_frame>
    <description>The descriptive statistics are presented as the number of participants having had coronary revascularization.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4745</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>colchicine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5 mg tablet of colchicine taken once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>colchicine placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.5 mg tablet of placebo taken once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>colchicine</intervention_name>
    <description>0.5 mg tablet taken once a day</description>
    <arm_group_label>colchicine</arm_group_label>
    <other_name>no other name</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>colchicine placebo</intervention_name>
    <description>sugar pill manufactured to mimic colchicine 0.5 mg tablet</description>
    <arm_group_label>colchicine placebo</arm_group_label>
    <other_name>no other name</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females of at least 18 years of age capable and willing to provide informed&#xD;
             consent&#xD;
&#xD;
          -  Patient must have suffered a documented acute myocardial infarction within the last 30&#xD;
             days&#xD;
&#xD;
          -  Patient must be treated according to national guidelines (including anti-platelet&#xD;
             therapy, statin, renin-angiotensin-aldosterone system inhibitor (preferably&#xD;
             angiotensin-converting enzyme) and beta-blocker when indicated)&#xD;
&#xD;
          -  Patient must have completed any planned percutaneous revascularization procedures&#xD;
             associated with his or her qualifying myocardial infarction&#xD;
&#xD;
          -  Female patient is either not of childbearing potential, defined as postmenopausal for&#xD;
             at least one year or surgically sterile, or is of childbearing potential and&#xD;
             practicing at least one method of contraception and preferably two complementary forms&#xD;
             of contraception&#xD;
&#xD;
          -  Patient is judged to be in good general health as determined by the principal&#xD;
             investigator&#xD;
&#xD;
          -  Patient must be able and willing to comply with the requirements of this study&#xD;
             protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with a poorly controlled medical condition, such as New York Heart Association&#xD;
             Class III-IV heart failure, a left ventricular ejection fraction of less than 35%,&#xD;
             recent stroke (within the past 3 months), or any other condition which in the opinion&#xD;
             of the investigator, would put the patient at risk if participating in this study&#xD;
&#xD;
          -  Patient with a Type 2 index MI (secondary to ischemic imbalance)&#xD;
&#xD;
          -  Patient with a prior coronary artery bypass graft within the past 3 years, or planned&#xD;
&#xD;
          -  Patient currently in cardiogenic shock or with hemodynamic instability&#xD;
&#xD;
          -  Patient with a history of cancer or lymphoproliferative disease within the last 3&#xD;
             years other than a successfully treated non-metastatic cutaneous squamous cell or&#xD;
             basal cell carcinoma and or localized carcinoma in situ of the cervix&#xD;
&#xD;
          -  Patient with inflammatory bowel disease (Crohn's disease or ulcerative colitis) or&#xD;
             patient with chronic diarrhea&#xD;
&#xD;
          -  Patient with pre-existent progressive neuromuscular disease or patient with creatine&#xD;
             phosphokinase level greater than 3 times the upper limit of normal (unless due to&#xD;
             myocardial infarction which is allowed) as measured within the past 30 days and&#xD;
             determined to be non-transient through repeat testing&#xD;
&#xD;
          -  Patient with any of the following as measured within the past 30 days, and determined&#xD;
             to be non-transient through repeat testing: hemoglobin less than 115 grams/L, white&#xD;
             blood cell count less than 3.0 X 10(9)/L,platelet count less than 110 X 10(9)/L,&#xD;
             alanine aminotransferase greater than 3 times the upper limit of normal, total&#xD;
             bilirubin greater than 2 times the upper limit of normal (unless due to Gilbert&#xD;
             syndrome, which is allowed), creatinine greater than 2 times the upper limit of normal&#xD;
&#xD;
          -  Patient with a history of cirrhosis, chronic active hepatitis or sever hepatic disease&#xD;
&#xD;
          -  Female patient who is pregnant, or breast-feeding or is considering becoming pregnant&#xD;
             during the study or for 6 months after the last dose of study medication&#xD;
&#xD;
          -  Patient with a history of clinically significant drug or alcohol abuse in the last&#xD;
             year&#xD;
&#xD;
          -  Patient is currently using or plan to begin chronic systemic steroid therapy (oral or&#xD;
             intravenous) during the study (topical or inhaled steroids are allowed)&#xD;
&#xD;
          -  Patient currently taking colchicine for other indications (mainly chronic indications&#xD;
             represented by Familial Mediterranean Fever or gout); there is no wash-out period&#xD;
             required for patients who have been treated with colchicine and stopped treatment&#xD;
             prior to enrollment&#xD;
&#xD;
          -  Patient with history of an allergic reaction or significant sensitivity to colchicine&#xD;
&#xD;
          -  Patient who has used an investigational chemical agent less than 30 days or 5&#xD;
             half-lives prior to the screening visit (whichever is longer)&#xD;
&#xD;
          -  Patient is considered by he investigator, for any reason, to be an unsuitable&#xD;
             candidate for the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Claude Tardif, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Orfanos, MD</last_name>
    <role>Study Director</role>
    <affiliation>Montreal Health Innovations Coordinating Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 26, 2015</study_first_submitted>
  <study_first_submitted_qc>September 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2015</study_first_posted>
  <results_first_submitted>July 17, 2020</results_first_submitted>
  <results_first_submitted_qc>September 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 19, 2020</results_first_posted>
  <last_update_submitted>September 23, 2020</last_update_submitted>
  <last_update_submitted_qc>September 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 28, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT02551094/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT02551094/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Colchicine</title>
          <description>0.5 mg tablet of colchicine taken once a day&#xD;
colchicine: 0.5 mg tablet taken once a day</description>
        </group>
        <group group_id="P2">
          <title>Colchicine Placebo</title>
          <description>0.5 mg tablet of placebo taken once a day&#xD;
colchicine placebo: sugar pill manufactured to mimic colchicine 0.5 mg tablet</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2366"/>
                <participants group_id="P2" count="2379"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2226"/>
                <participants group_id="P2" count="2232"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="147"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Colchicine</title>
          <description>0.5 mg tablet of colchicine taken once a day&#xD;
colchicine: 0.5 mg tablet taken once a day</description>
        </group>
        <group group_id="B2">
          <title>Colchicine Placebo</title>
          <description>0.5 mg tablet of placebo taken once a day&#xD;
colchicine placebo: sugar pill manufactured to mimic colchicine 0.5 mg tablet</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2366"/>
            <count group_id="B2" value="2379"/>
            <count group_id="B3" value="4745"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.6" spread="10.7"/>
                    <measurement group_id="B2" value="60.5" spread="10.6"/>
                    <measurement group_id="B3" value="60.6" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="472"/>
                    <measurement group_id="B2" value="437"/>
                    <measurement group_id="B3" value="909"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1894"/>
                    <measurement group_id="B2" value="1942"/>
                    <measurement group_id="B3" value="3836"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnic Origin</title>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian and Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American and Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American and Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Caucasion</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1350"/>
                    <measurement group_id="B2" value="1329"/>
                    <measurement group_id="B3" value="2679"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Caucasian and Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="377"/>
                    <measurement group_id="B2" value="381"/>
                    <measurement group_id="B3" value="758"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Indian ancestry</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Metis, aboriginal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>North African / Middle Eastern</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
                <category>
                  <title>France n=1051 (Ethnic origin was not provided</title>
                  <measurement_list>
                    <measurement group_id="B1" value="516"/>
                    <measurement group_id="B2" value="535"/>
                    <measurement group_id="B3" value="1051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="230"/>
                    <measurement group_id="B2" value="226"/>
                    <measurement group_id="B3" value="456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="739"/>
                    <measurement group_id="B2" value="744"/>
                    <measurement group_id="B3" value="1483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="516"/>
                    <measurement group_id="B2" value="535"/>
                    <measurement group_id="B3" value="1051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="270"/>
                    <measurement group_id="B2" value="260"/>
                    <measurement group_id="B3" value="530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lebanon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tunisia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>First Event of Cardiovascular Death, Resuscitated Cardiac Arrest, Acute Myocardial Infarction, Stroke, or Urgent Hospitalization for Angina Requiring Coronary Revascularization</title>
        <description>The descriptive statistics are the number of participants having at least one of the composites of the primary endpoint.</description>
        <time_frame>From randomization to occurence of first event, assessed up to 3.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colchicine Placebo</title>
            <description>0.5 mg tablet of placebo taken once a day&#xD;
colchicine placebo: sugar pill manufactured to mimic colchicine 0.5 mg tablet</description>
          </group>
          <group group_id="O2">
            <title>Colchicine</title>
            <description>0.5 mg tablet of colchicine taken once a day&#xD;
colchicine: 0.5 mg tablet taken once a day</description>
          </group>
        </group_list>
        <measure>
          <title>First Event of Cardiovascular Death, Resuscitated Cardiac Arrest, Acute Myocardial Infarction, Stroke, or Urgent Hospitalization for Angina Requiring Coronary Revascularization</title>
          <description>The descriptive statistics are the number of participants having at least one of the composites of the primary endpoint.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2379"/>
                <count group_id="O2" value="2366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170"/>
                    <measurement group_id="O2" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death (Total Mortality)</title>
        <description>The descriptive statistics are the number of participants having deceased.</description>
        <time_frame>From randomization to death, assessed up to 3.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colchicine Placebo</title>
            <description>0.5 mg tablet of placebo taken once a day&#xD;
colchicine placebo: sugar pill manufactured to mimic colchicine 0.5 mg tablet</description>
          </group>
          <group group_id="O2">
            <title>Colchicine</title>
            <description>0.5 mg tablet of colchicine taken once a day&#xD;
colchicine: 0.5 mg tablet taken once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Death (Total Mortality)</title>
          <description>The descriptive statistics are the number of participants having deceased.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2379"/>
                <count group_id="O2" value="2366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiovascular Death</title>
        <description>The descriptive statistics are presented as the number of participants having had a cardiovascular death.</description>
        <time_frame>From randomization to death, assessed up to 3.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colchicine Placebo</title>
            <description>0.5 mg tablet of placebo taken once a day&#xD;
colchicine placebo: sugar pill manufactured to mimic colchicine 0.5 mg tablet</description>
          </group>
          <group group_id="O2">
            <title>Colchicine</title>
            <description>0.5 mg tablet of colchicine taken once a day&#xD;
colchicine: 0.5 mg tablet taken once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiovascular Death</title>
          <description>The descriptive statistics are presented as the number of participants having had a cardiovascular death.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2379"/>
                <count group_id="O2" value="2366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resuscitated Cardiac Arrest</title>
        <description>The descriptive statistics are presented as the number of participants having had resuscitated cardiac arrest</description>
        <time_frame>From randomization to event, assessed up to 3.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colchicine Placebo</title>
            <description>0.5 mg tablet of placebo taken once a day&#xD;
colchicine placebo: sugar pill manufactured to mimic colchicine 0.5 mg tablet</description>
          </group>
          <group group_id="O2">
            <title>Colchicine</title>
            <description>0.5 mg tablet of colchicine taken once a day&#xD;
colchicine: 0.5 mg tablet taken once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Resuscitated Cardiac Arrest</title>
          <description>The descriptive statistics are presented as the number of participants having had resuscitated cardiac arrest</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2379"/>
                <count group_id="O2" value="2366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction</title>
        <description>The descriptive statistics are presented as the number of participants having had myocardial infarction.</description>
        <time_frame>From randomization to event, assessed up to 3.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colchicine Placebo</title>
            <description>0.5 mg tablet of placebo taken once a day&#xD;
colchicine placebo: sugar pill manufactured to mimic colchicine 0.5 mg tablet</description>
          </group>
          <group group_id="O2">
            <title>Colchicine</title>
            <description>0.5 mg tablet of colchicine taken once a day&#xD;
colchicine: 0.5 mg tablet taken once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Infarction</title>
          <description>The descriptive statistics are presented as the number of participants having had myocardial infarction.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2379"/>
                <count group_id="O2" value="2366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stroke</title>
        <description>The descriptive statistics are presented as the number of participants having had a stroke.</description>
        <time_frame>From randomization to event, assessed up to 3.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colchicine Placebo</title>
            <description>0.5 mg tablet of placebo taken once a day&#xD;
colchicine placebo: sugar pill manufactured to mimic colchicine 0.5 mg tablet</description>
          </group>
          <group group_id="O2">
            <title>Colchicine</title>
            <description>0.5 mg tablet of colchicine taken once a day&#xD;
colchicine: 0.5 mg tablet taken once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Stroke</title>
          <description>The descriptive statistics are presented as the number of participants having had a stroke.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2379"/>
                <count group_id="O2" value="2366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urgent Hospitalization for Angina Requiring Coronary Revascularization</title>
        <description>The descriptive statistics are presented as the number of participants having had urgent hospitalization for angina requiring coronary revascularization.</description>
        <time_frame>From randomization to event, assessed up to 3.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colchicine Placebo</title>
            <description>0.5 mg tablet of placebo taken once a day&#xD;
colchicine placebo: sugar pill manufactured to mimic colchicine 0.5 mg tablet</description>
          </group>
          <group group_id="O2">
            <title>Colchicine</title>
            <description>0.5 mg tablet of colchicine taken once a day&#xD;
colchicine: 0.5 mg tablet taken once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Urgent Hospitalization for Angina Requiring Coronary Revascularization</title>
          <description>The descriptive statistics are presented as the number of participants having had urgent hospitalization for angina requiring coronary revascularization.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2379"/>
                <count group_id="O2" value="2366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>First Event of Cardiovascular Death, Resuscitated Cardiac Arrest, Acute MI or Stroke.</title>
        <description>The descriptive statistics are presented as the number of participants having had a first event of cardiovascular death, resuscitated cardiac arrest, acute MI or stroke.</description>
        <time_frame>From randomization to occurence of first event, assessed up to 3.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colchicine Placebo</title>
            <description>0.5 mg tablet of placebo taken once a day&#xD;
colchicine placebo: sugar pill manufactured to mimic colchicine 0.5 mg tablet</description>
          </group>
          <group group_id="O2">
            <title>Colchicine</title>
            <description>0.5 mg tablet of colchicine taken once a day&#xD;
colchicine: 0.5 mg tablet taken once a day</description>
          </group>
        </group_list>
        <measure>
          <title>First Event of Cardiovascular Death, Resuscitated Cardiac Arrest, Acute MI or Stroke.</title>
          <description>The descriptive statistics are presented as the number of participants having had a first event of cardiovascular death, resuscitated cardiac arrest, acute MI or stroke.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2379"/>
                <count group_id="O2" value="2366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>First Event of Deep Venous Thrombosis or Pulmonary Embolus</title>
        <description>The descriptive statistics are presented as the number of participants having had a first event of deep venous thrombosis or pulmonary embolus.</description>
        <time_frame>From randomization to occurence of first event, assessed up to 3.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colchicine Placebo</title>
            <description>0.5 mg tablet of placebo taken once a day&#xD;
colchicine placebo: sugar pill manufactured to mimic colchicine 0.5 mg tablet</description>
          </group>
          <group group_id="O2">
            <title>Colchicine</title>
            <description>0.5 mg tablet of colchicine taken once a day&#xD;
colchicine: 0.5 mg tablet taken once a day</description>
          </group>
        </group_list>
        <measure>
          <title>First Event of Deep Venous Thrombosis or Pulmonary Embolus</title>
          <description>The descriptive statistics are presented as the number of participants having had a first event of deep venous thrombosis or pulmonary embolus.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2379"/>
                <count group_id="O2" value="2366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Atrial Fibrillation</title>
        <description>The descriptive statistics are presented as the number of participants having had atrial fibrillation.</description>
        <time_frame>From randomization to event, assessed up to 3.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colchicine Placebo</title>
            <description>0.5 mg tablet of placebo taken once a day&#xD;
colchicine placebo: sugar pill manufactured to mimic colchicine 0.5 mg tablet</description>
          </group>
          <group group_id="O2">
            <title>Colchicine</title>
            <description>0.5 mg tablet of colchicine taken once a day&#xD;
colchicine: 0.5 mg tablet taken once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Atrial Fibrillation</title>
          <description>The descriptive statistics are presented as the number of participants having had atrial fibrillation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2379"/>
                <count group_id="O2" value="2366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Heart Failure Hospitalization</title>
        <description>The descriptive statistics are presented as the number of participants having had heart failure hospitalization.</description>
        <time_frame>From randomization to event, assessed up to 3.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colchicine Placebo</title>
            <description>0.5 mg tablet of placebo taken once a day&#xD;
colchicine placebo: sugar pill manufactured to mimic colchicine 0.5 mg tablet</description>
          </group>
          <group group_id="O2">
            <title>Colchicine</title>
            <description>0.5 mg tablet of colchicine taken once a day&#xD;
colchicine: 0.5 mg tablet taken once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Failure Hospitalization</title>
          <description>The descriptive statistics are presented as the number of participants having had heart failure hospitalization.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2379"/>
                <count group_id="O2" value="2366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Coronary Revascularization</title>
        <description>The descriptive statistics are presented as the number of participants having had coronary revascularization.</description>
        <time_frame>From randomization to event, assessed up to 3.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colchicine Placebo</title>
            <description>0.5 mg tablet of placebo taken once a day&#xD;
colchicine placebo: sugar pill manufactured to mimic colchicine 0.5 mg tablet</description>
          </group>
          <group group_id="O2">
            <title>Colchicine</title>
            <description>0.5 mg tablet of colchicine taken once a day&#xD;
colchicine: 0.5 mg tablet taken once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Coronary Revascularization</title>
          <description>The descriptive statistics are presented as the number of participants having had coronary revascularization.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2379"/>
                <count group_id="O2" value="2366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The time period covered was from randomization to last follow up which lasted 3.5 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Colchicine Placebo</title>
          <description>0.5 mg tablet of placebo taken once a day&#xD;
colchicine placebo: sugar pill manufactured to mimic colchicine 0.5 mg tablet</description>
        </group>
        <group group_id="E2">
          <title>Colchicine</title>
          <description>0.5 mg tablet of colchicine taken once a day&#xD;
colchicine: 0.5 mg tablet taken once a day</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="2346"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="2330"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="404" subjects_at_risk="2346"/>
                <counts group_id="E2" subjects_affected="383" subjects_at_risk="2330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>HF hospitalization SAE</sub_title>
                <counts group_id="E1" events="371" subjects_affected="17" subjects_at_risk="2346"/>
                <counts group_id="E2" events="383" subjects_affected="25" subjects_at_risk="2330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastro-intestinal SAE</sub_title>
                <counts group_id="E1" events="404" subjects_affected="36" subjects_at_risk="2346"/>
                <counts group_id="E2" events="383" subjects_affected="46" subjects_at_risk="2330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="404" subjects_affected="319" subjects_at_risk="2346"/>
                <counts group_id="E2" events="383" subjects_affected="263" subjects_at_risk="2330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection SAE</sub_title>
                <counts group_id="E1" events="404" subjects_affected="38" subjects_at_risk="2346"/>
                <counts group_id="E2" events="383" subjects_affected="51" subjects_at_risk="2330"/>
              </event>
              <event>
                <sub_title>Septic Shock SAE</sub_title>
                <counts group_id="E1" events="404" subjects_affected="2" subjects_at_risk="2346"/>
                <counts group_id="E2" events="383" subjects_affected="2" subjects_at_risk="2330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia SAE</sub_title>
                <counts group_id="E1" events="404" subjects_affected="9" subjects_at_risk="2346"/>
                <counts group_id="E2" events="383" subjects_affected="21" subjects_at_risk="2330"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="371" subjects_at_risk="2346"/>
                <counts group_id="E2" subjects_affected="372" subjects_at_risk="2330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia AE</sub_title>
                <counts group_id="E1" events="371" subjects_affected="10" subjects_at_risk="2346"/>
                <counts group_id="E2" events="372" subjects_affected="14" subjects_at_risk="2330"/>
              </event>
              <event>
                <sub_title>Leukopenia AE</sub_title>
                <counts group_id="E1" events="371" subjects_affected="3" subjects_at_risk="2346"/>
                <counts group_id="E2" events="372" subjects_affected="2" subjects_at_risk="2330"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia AE</sub_title>
                <counts group_id="E1" events="371" subjects_affected="7" subjects_at_risk="2346"/>
                <counts group_id="E2" events="372" subjects_affected="3" subjects_at_risk="2330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nauseau AE</sub_title>
                <counts group_id="E1" events="371" subjects_affected="24" subjects_at_risk="2346"/>
                <counts group_id="E2" events="372" subjects_affected="43" subjects_at_risk="2330"/>
              </event>
              <event>
                <sub_title>Flatulence AE</sub_title>
                <counts group_id="E1" events="371" subjects_affected="5" subjects_at_risk="2346"/>
                <counts group_id="E2" events="372" subjects_affected="15" subjects_at_risk="2330"/>
              </event>
              <event>
                <sub_title>GI Haemorrhage AE</sub_title>
                <counts group_id="E1" events="371" subjects_affected="5" subjects_at_risk="2346"/>
                <counts group_id="E2" events="372" subjects_affected="7" subjects_at_risk="2330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="371" subjects_affected="109" subjects_at_risk="2346"/>
                <counts group_id="E2" events="372" subjects_affected="63" subjects_at_risk="2330"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea AE</sub_title>
                <counts group_id="E1" events="371" subjects_affected="208" subjects_at_risk="2346"/>
                <counts group_id="E2" events="372" subjects_affected="225" subjects_at_risk="2330"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jean-Claude Tardif (Principle Investigator)</name_or_title>
      <organization>Montreal Heart Institute</organization>
      <phone>514-376-3330 ext 3612</phone>
      <email>jean-claude.tardif@icm-mhi.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

